© 2005 Foundation for Promotion of Cancer Research
Phase II Study of Carboplatin–Paclitaxel Combination Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer
1 Department of Respiratory Medicine, Graduate School of Medical Science, Kumamoto University, Kumamoto and 2 Department of Medical Oncology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan
For reprints and all correspondence: Isamu Okamoto, Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. E-mail: okamoto{at}dotd.med.kindai.ac.jp
Received December 2, 2004; accepted February 15, 2005
Background: More than 30% of cases of non-small cell lung cancer (NSCLC) arise in patients aged 
70 years. The efficacy and safety of carboplatin–paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial.
Methods: Twenty-five patients aged 70 years (median, 76; range, 70–83) with chemotherapy-naïve advanced NSCLC were enrolled between January 2001 and July 2003. Additional criteria included the presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients received carboplatin at an area under the curve of 5 mg/ml/min and paclitaxel at 180 mg/m2 on the first day of consecutive 3 week periods.
Results: The patients included four with stage IIIB, 19 with stage IV and two with recurrent disease. The median number of treatment cycles was three (range, 1–4). One complete response and six partial responses, yielding an objective response rate of 28%, were obtained. The median survival time was 12.3 months and the 1-year survival rate was 52%. Hematological toxicities of grade 3 or 4 included leukopenia (40%), neutropenia (68%) and anemia (4%). Non-hematological toxicities of grade 3 included arthralgia–myalgia (16%) and neuropathy (12%). The objective response rate for patients aged 75 years (n = 15) was 26%, and no evidence of excessive toxicity in these patients was apparent compared with those aged <75 years.
Conclusion: The combination carboplatin–paclitaxel at these doses is a feasible treatment option with a favorable toxicity profile for fit elderly patients with advanced NSCLC.
Key Words: non-small cell lung cancer • elderly patients • carboplatin • paclitaxel
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Ramalingam and F. R. Khuri The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer Oncologist, April 1, 2009; 14(4): 412 - 424. [Abstract] [Full Text] [PDF]
|
|